[144] BorgWarner Inc. SEC Filing
BorgWarner Inc. (BWA) Form 144 shows a proposed sale of 3,000 common shares through Charles Schwab & Co., with an aggregate market value of $130,350 and an approximate sale date of 09/04/2025 on the NYSE. The shares were acquired on 02/05/2025 via a performance stock lapse from BorgWarner Inc. The filing identifies prior disposals by the same person, Isabelle McKenzie, of 10,190 shares during August 2025, generating total gross proceeds of $404,045. Outstanding shares listed are 216,392,876. The filer certifies absence of undisclosed material adverse information and notes compliance with Rule 144 disclosure requirements.
- None.
- Insider selling activity: The reporting person sold 10,190 shares in August 2025 and intends to sell an additional 3,000 shares on 09/04/2025, which could be perceived negatively by some investors despite immaterial size.
- Concentration of transactions: Multiple sales by the same individual in a short period may prompt investor questions about insider liquidity or timing.
Insights
Routine Rule 144 filing: small insider disposition relative to market cap, limited immediate market impact.
The Form 144 documents a planned sale of 3,000 common shares by an insider who received the shares via a performance stock lapse earlier in 2025. Prior August sales totaling 10,190 shares produced $404,045 in gross proceeds. Compared with the 216 million shares outstanding, these volumes are immaterial and unlikely to affect share price materially. The disclosure satisfies regulatory requirements and provides transparency on insider liquidity events; no information in the filing indicates undisclosed adverse developments at the issuer.
Compliance-focused disclosure showing insider monetization of vested compensation, standard governance transparency.
The filing records an insider selling equity received from a performance award and lists recent open-market sales by the same individual. This is a standard governance event: reporting via Form 144 notifies the market of intended Rule 144 sales and helps ensure trading conforms with securities law. There are no allegations, restrictions, or unusual terms disclosed, and the signer affirms no undisclosed material adverse facts. From a governance perspective, the filing appears complete for the transaction described.